{"filings":[{"id":696156,"accession_number":"0001140361-26-022984","cik":1671927,"company_name":"Immunocore Holdings plc","ticker":"IMCR","form_type":"8-K","filed_at":"2026-05-27T20:21:47+00:00","items":["5.07"],"status":"ready","headline":"Immunocore shareholders approve all 10 resolutions at 2026 AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Reappointment of directors Siddharth Kaul, William Pao, Kristine Peterson passed; Peterson had 8.7M against (22.5%).","Advisory say-on-pay (Resolution 4) passed with 29.7M for, 8.6M against (22.5% opposition).","Ratification of Deloitte as US independent auditor and UK statutory auditors passed overwhelmingly.","Directors' remuneration report (Resolution 9) approved with 29.5M for, 8.7M against (22.8% opposition).","Authorization for political donations (Resolution 10) passed with 38.2M for, 82K against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1449726610.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94564,"accession_number":"0001140361-26-019205","cik":1671927,"company_name":"Immunocore Holdings plc","ticker":"IMCR","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunocore Q1 KIMMTRAK net sales $106.7M (+14% YoY); net income $13M vs $5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["KIMMTRAK net sales $106.7M, up 14% YoY; US sales $67.4M (+19.1% YoY), Europe $34.4M.","Net income $13.0M ($0.25 diluted EPS) vs $5.0M ($0.10) in Q1 2025.","Five-year OS data at AACR: KIMMTRAK OS rate 16% vs 8% control in metastatic uveal melanoma (HR 0.67).","Cash and marketable securities $845M; R&D expense $61.1M, SG&A $37.9M.","Phase 3 TEBE-AM (cutaneous melanoma) enrollment expected to complete H1 2026; topline data H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":106677000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1449726610.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107044,"accession_number":"0001140361-26-006721","cik":1671927,"company_name":"Immunocore Holdings plc","ticker":"IMCR","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunocore reports Q4 2025 KIMMTRAK sales of $104.5M, FY $400M; TEBE-AM data 2H 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 KIMMTRAK net sales $104.5M (+24% YoY); FY2025 $400.0M (+29% YoY).","FY2025 net loss narrowed to $35.5M from $51.1M in 2024; cash $864.2M.","R&D spend rose to $274.9M (FY2025) on autoimmune programs and Phase 3 trials.","TEBE-AM Phase 3 enrollment complete 1H 2026; topline OS data expected 2H 2026.","PRAME and HIV clinical data presentations expected 2H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":400016000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1449726610.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107043,"accession_number":"0001140361-26-002894","cik":1671927,"company_name":"Immunocore Holdings plc","ticker":"IMCR","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Immunocore R&D Head David Berman resigns effective Feb 27; no replacement planned","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Berman notified resignation as Head of R&D on Jan 27, 2026, effective Feb 27, 2026.","Resignation is voluntary to pursue another opportunity; not due to any disagreement with the Company.","Company will not seek a direct replacement; will streamline and leverage existing R&D structure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1449726610.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107042,"accession_number":"0001140361-26-000780","cik":1671927,"company_name":"Immunocore Holdings plc","ticker":"IMCR","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Immunocore reports prelim cash $864M, sets 2026 priorities including TEBE-AM enrollment completion in 1H 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary unaudited cash, cash equivalents and marketable securities ~$864M as of Dec 31, 2025.","TEBE-AM Phase 3 cutaneous melanoma trial enrollment completion expected 1H 2026; topline data as early as 2H 2026.","Phase 1/2 PRAME data expected 2H 2026: brenetafusp combos in ovarian and NSCLC, initial IMC-P115C data.","First patient in Phase 1 type 1 diabetes trial (IMC-S118AI) expected 1H 2026; autoimmune trial app for atopic dermatitis in 2H 2026.","KIMMTRAK enters 5th year post-approval; expects moderate revenue growth driven by community and global penetration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1449726610.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123383,"accession_number":"0001140361-25-043600","cik":1671927,"company_name":"Immunocore Holdings plc","ticker":"IMCR","form_type":"8-K","filed_at":"2025-11-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Immunocore board member Krishana resigns; CHRO St. Leger to depart in May 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ranjeev Krishana resigned from Board and Remuneration Committee effective Nov 26, 2025; no disagreement with company.","CHRO Tina St. Leger will resign effective May 26, 2026 to pursue other opportunity; company has begun formal search for replacement.","Both departures are not due to any disagreement over operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1449726610.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123382,"accession_number":"0001140361-25-040664","cik":1671927,"company_name":"Immunocore Holdings plc","ticker":"IMCR","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunocore Q3 2025 KIMMTRAK sales $103.7M, up 29% YoY; net loss $0.2M vs profit $8.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["KIMMTRAK net revenue $103.7M (Q3); $295.5M YTD, up 31% YoY; US sales $67.3M, Europe $33.5M.","Net loss $(0.2)M vs profit $8.7M in Q3 2024; diluted EPS $(0.00) vs $0.17.","IDMC recommended 160 mcg dose for brenetafusp in Phase 3 PRISM-MEL-301; on track to complete enrollment in 1H 2026.","Cash, equivalents & marketable securities $892.4M as of Sept 30, 2025; expects $65M rebate payments in Q4.","Phase 3 TEBE-AM (tebentafusp) enrollment on track for 1H 2026 completion; multiple pipeline programs advancing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":295538000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1449726610.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140045,"accession_number":"0001140361-25-029350","cik":1671927,"company_name":"Immunocore Holdings plc","ticker":"IMCR","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunocore Q2 2025: KIMMTRAK revenue $98M (+30% YoY); net loss $10.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 net product sales of $98.0M, up 30% vs. $75.3M in Q2 2024; US sales $64.1M, Europe $33.0M.","Net loss of $10.3M ($0.20 per share) compared to net loss of $11.6M ($0.23 per share) in Q2 2024.","Cash, equivalents & marketable securities of $882.8M as of June 30, 2025; expects ~$65M in rebate payouts.","Phase 3 TEBE-AM trial (cutaneous melanoma) on track to complete enrollment in 1H 2026.","PRISM-MEL-301 (brenetafusp) dose selection expected in 2H 2025; IDMC recommended continue with no changes."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":191845000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1449726610.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157689,"accession_number":"0001140361-25-019282","cik":1671927,"company_name":"Immunocore Holdings plc","ticker":"IMCR","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Immunocore 2025 AGM: all 13 resolutions passed, director Herbst re-elected with narrow margin","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Re-appointment of director Roy S. Herbst: 17.3M for, 15.5M against (47% oppose).","Advisory say-on-pay passed: 27.8M for, 4.9M against.","Ratification of Deloitte as U.S. auditors passed: 32.7M for, 1.5K against.","Directors' remuneration report and policy both approved with ~27.9M for each.","Authority to allot shares up to £150K nominal and to allot for cash passed (special resolution)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1449726610.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157688,"accession_number":"0001140361-25-017615","cik":1671927,"company_name":"Immunocore Holdings plc","ticker":"IMCR","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunocore Q1: KIMMTRAK revenue $93.9M (+33% YoY); net income $5M vs loss year ago","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["KIMMTRAK net sales $93.9M, up 33% YoY; US $56.6M, Europe $32.8M (incl $6M favorable adjustments), intl $4.5M.","Net income $5.0M vs net loss $24.4M in Q1 2024; diluted EPS $0.10 vs ($0.49).","Phase 3 TEBE-AM (cutaneous melanoma) enrollment on track to complete in 1H 2026; PRISM-MEL-301 dose selection expected 2H 2025.","HIV candidate IMC-M113V showed viral control in 3 of 15 evaluable patients at CROI; dose escalation continuing.","Cash and securities $837M at March 31, 2025, up from $820.4M at Dec 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":93881000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1449726610.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176064,"accession_number":"0001140361-25-008918","cik":1671927,"company_name":"Immunocore Holdings plc","ticker":"IMCR","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immunocore registers up to $150M of 2.50% convertible notes for resale by selling holders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement on March 17, 2025 covering resale of up to $150M aggregate principal of 2.50% Convertible Senior Notes due 2030.","Entered first supplemental indenture to add Trust Indenture Act provisions; legal opinions from Cooley (UK) LLP and Cooley LLP attached.","Selling securityholders may also resell ADSs and ordinary shares issuable upon conversion of the notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1449726610.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176063,"accession_number":"0001140361-25-007867","cik":1671927,"company_name":"Immunocore Holdings plc","ticker":"IMCR","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Immunocore HIV cure candidate IMC-M113V shows dose-dependent viral control in Phase 1/2 MAD data at CROI 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Well tolerated across 60-300 mcg doses; no dose-limiting toxicities or serious AEs; mild CRS in 5 of 6 at 300 mcg.","3 of 15 evaluable PLWH showed delayed viral rebound or viremia control after ART interruption; 2 remained off ART for full 12 weeks.","Dose-dependent reduction in active reservoir (CD4+ Gag RNA) and trend of intact HIV DNA reduction at higher doses.","Enrollment continues with higher doses; expansion cohorts planned at one or more doses.","IMC-M113V is first TCR bispecific targeting HIV in clinic, aims for functional cure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1449726610.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176062,"accession_number":"0001140361-25-005988","cik":1671927,"company_name":"Immunocore Holdings plc","ticker":"IMCR","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Immunocore reports 2024 KIMMTRAK net sales of $310M; appoints William Pao to board","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["KIMMTRAK Q4 net sales $84.1M; full year $310.0M (+30% YoY); net loss $51.1M ($1.02 EPS) vs $55.3M in 2023.","Ended 2024 with $820.4M cash; repaid $50M Pharmakon loan in Nov 2024.","Advanced PRAME pipeline: Phase 3 PRISM-MEL-301 enrolled first patient; IMC-P115C and IMC-R117C first doses in Phase 1.","Appointed Dr. William Pao (CEO of Revelio Therapeutics) as non-executive director effective Feb 25, 2025.","Expects to present initial HIV data (IMC-M113V) in Q1 2025 and HBV data (IMC-I109V) in H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":310202000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1449726610.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176061,"accession_number":"0001140361-25-000837","cik":1671927,"company_name":"Immunocore Holdings plc","ticker":"IMCR","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Immunocore reports ~$820M cash; three Phase 3 melanoma trials; new autoimmune candidate","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash ~$820M as of Dec 31, 2024; Pharmakon loan prepaid in full.","Three Phase 3 trials enrolling in melanoma (TEBE-AM, PRISM-MEL-301, ATOM); first topline data expected 2026.","New autoimmune candidate IMC-U120AI (CD1a x PD1) for atopic dermatitis; CTA planned 2026.","Initial HIV Phase 1 multiple ascending dose data for IMC-M113V expected Q1 2025.","Travis Coy appointed EVP, CFO and Head of Corporate Development (ex-Eli Lilly)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1449726610.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176060,"accession_number":"0001140361-25-000008","cik":1671927,"company_name":"Immunocore Holdings plc","ticker":"IMCR","form_type":"8-K","filed_at":"2025-01-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Immunocore appoints Travis Coy as EVP, CFO, Head of Corporate Development effective Jan 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Annual base salary $500,000; target cash bonus 40% of salary; sign-on bonus $200,000 in three installments.","Grant of 274,033 options under 2021 Equity Incentive Plan, vesting over 4 years (25% at 1-year anniversary, then quarterly).","Mr. Coy brings over 20 years at Eli Lilly, most recently VP, Head of Transactions and M&A.","Severance: 18 months base salary plus 150% target bonus if terminated without cause within 18 months of change of control; 12 months base otherwise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1449726610.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192978,"accession_number":"0001140361-24-045855","cik":1671927,"company_name":"Immunocore Holdings plc","ticker":"IMCR","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Immunocore prepays $52M Pharmakon loan, terminating agreement 4 years early","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Immunocore prepaid $52M ($50M principal, $0.5M interest, $1.5M prepayment premium) on Nov 8, 2024.","Full repayment terminates all obligations under Pharmakon Loan Agreement originally due Nov 8, 2028.","Loan was from BioPharma Credit entities; collateral agent BioPharma Credit PLC.","Subsidiary Immunocore Limited was borrower; parent Immunocore Holdings as credit party."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1449726610.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192977,"accession_number":"0001140361-24-045343","cik":1671927,"company_name":"Immunocore Holdings plc","ticker":"IMCR","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunocore Q3 2024: KIMMTRAK revenue $80.2M (+28% YoY); EPS $0.17; CFO to depart","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["KIMMTRAK net revenue $80.2M in Q3 2024, up 28% vs $62.6M in Q3 2023; US $57.3M, Europe $21.0M.","GAAP EPS $0.17 (diluted), net income $8.7M vs $0.9M in Q3 2023; cash $901.3M at Sept 30, 2024.","CFO Brian Di Donato to leave end of 2024; search for replacement in progress.","Brenetafusp (PRAME-A02) Phase 1 data at ESMO; NSCLC signal-detection shift delays initial data release.","Plans to repay $50M loan by end of 2024; pay ~$40M in sales-related rebate accruals in Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":226150000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1449726610.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209348,"accession_number":"0001140361-24-041100","cik":1671927,"company_name":"Immunocore Holdings plc","ticker":"IMCR","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immunocore reports positive Phase 1 data for brenetafusp in ovarian cancer at ESMO 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 monotherapy: 58% disease control, 6.5% RECIST response rate, median PFS 3.3 months in heavily pre-treated platinum-resistant ovarian cancer.","Phase 1 combo with chemo: 23% RECIST response rate, 69% disease control, 82% ctDNA molecular response rate.","T cell fitness signature associated with OS (28 vs 11 months) and PFS (5 vs 2 months) for KIMMTRAK in uveal melanoma, across ImmTAC platform.","Brenetafusp well tolerated; no treatment-related discontinuations; cytokine release syndrome manageable (57% Grade 1)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1449726610.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209347,"accession_number":"0001140361-24-039083","cik":1671927,"company_name":"Immunocore Holdings plc","ticker":"IMCR","form_type":"8-K","filed_at":"2024-08-29T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Immunocore CFO Brian Di Donato resigns, effective Dec 31, 2024, to become CEO at private biotech","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO and Head of Strategy Brian Di Donato resigns effective Dec 31, 2024, to become CEO at a private early-stage biotech in San Diego.","Resignation not due to any disagreement with Immunocore on financials, internal controls, or policies.","Di Donato remains through year-end to ensure smooth transition; formal CFO search initiated.","Di Donato joined over 4 years ago, led IPO and built Finance department."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1449726610.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209346,"accession_number":"0001140361-24-036283","cik":1671927,"company_name":"Immunocore Holdings plc","ticker":"IMCR","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunocore reports Q2 2024 revenue growth of 32% driven by KIMMTRAK sales of $75.3 million","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["KIMMTRAK net revenues were $75.3 million in Q2 2024, up 32% year-over-year, driven by US growth and global expansion.","Registrational Phase 3 TEBE-AM trial for KIMMTRAK in cutaneous melanoma converted from Phase 2/3; enrollment completion expected in 1H 2026.","First patient randomized in Phase 3 PRISM-MEL-301 trial evaluating brenetafusp + nivolumab in first-line cutaneous melanoma.","Cash and equivalents at $859.6 million; company plans to repay $50 million loan by end of 2024.","Net loss narrowed to $11.6 million from $17.0 million in prior year quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":145902000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1449726610.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227339,"accession_number":"0001140361-24-028366","cik":1671927,"company_name":"Immunocore Holdings plc","ticker":"IMCR","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Immunocore reports Phase 1 brenetafusp data: 56% disease control in checkpoint pre-treated melanoma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Brenetafusp monotherapy in 47 late-line cutaneous melanoma patients showed 56% DCR (4 PR, 16 SD) and 4.2 months median PFS in PRAME+ patients.","ctDNA molecular response in 42% of PRAME+ patients; trend for longer PFS/OS in molecular responders.","Combination with pembrolizumab well tolerated; 4/7 evaluable patients achieved disease control including 1 ongoing PR.","T cell fitness gene signature: high expression associated with 6-month median PFS and 69% DCR vs 2 months/42% for low.","Phase 3 PRISM-MEL-301 trial (brenetafusp + nivolumab) enrolling first-line advanced melanoma patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1449726610.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227338,"accession_number":"0001140361-24-028194","cik":1671927,"company_name":"Immunocore Holdings plc","ticker":"IMCR","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immunocore converts TEBE-AM to registrational Phase 3 evaluating KIMMTRAK for cutaneous melanoma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Trial converted to Phase 3 registrational after FDA consultation; three arms: KIMMTRAK monotherapy, KIMMTRAK+pembrolizumab, control.","All patients randomized from trial start included in Phase 3 intent-to-treat population; time to final OS analysis expected to accelerate.","Phase 3 to test KIMMTRAK in previously treated advanced cutaneous melanoma; rapid accrual made Phase 2 OS maturity timeline moot.","Phase 1b data showed ~75% one-year OS rate for KIMMTRAK+checkpoint combo in metastatic cutaneous melanoma patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1449726610.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227337,"accession_number":"0001140361-24-027667","cik":1671927,"company_name":"Immunocore Holdings plc","ticker":"IMCR","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Immunocore appoints Baker Bros partner Krishana to board; grants registration rights to BBA funds","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Ranjeev Krishana (Baker Bros partner) as Class I director, effective May 28, 2024.","Standard director compensation includes option grant valued at ~$325,790.","Entered Registration Rights Agreement with BBA funds for resale of shares held by them.","BBA can request resale registration within 60 days; up to one underwritten offering per year.","Amendment lowered director nomination threshold from 75% of shares to fixed 1,029,652 ADSs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1449726610.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227336,"accession_number":"0001140361-24-027312","cik":1671927,"company_name":"Immunocore Holdings plc","ticker":"IMCR","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Immunocore shareholders re-elect all directors, approve executive compensation, ratify Deloitte at 2024 AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Bahija Jallal re-elected with 34.24M for (99.96%); Sir John Bell re-elected with 30.13M for (87.95%).","Advisory say-on-pay passed with 33.62M for (98.07%); shareholders chose 'One Year' frequency (34.21M votes).","Deloitte LLP ratified as U.S. independent auditor for 2024 with 34.26M for (99.99%).","New articles of association adopted as special resolution with 34.25M for (99.99%).","Directors' remuneration report for 2023 approved with 33.72M for (98.44%)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1449726610.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227335,"accession_number":"0001140361-24-024789","cik":1671927,"company_name":"Immunocore Holdings plc","ticker":"IMCR","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunocore Q1 KIMMTRAK sales $70.3M (+36% YoY); brenetafusp ASCO data; cash $832.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["KIMMTRAK net sales $70.3M, up 36% YoY; US $50.0M, Europe $19.0M, international $1.4M.","Net loss $24.4M ($0.49/sh) vs $19.4M ($0.40/sh) in Q1 2023; R&D $57.5M, SG&A $39.3M.","Cash $832.8M as of Mar 31, 2024, including $390.2M net from Feb 2024 convertible notes; plans to repay $50M loan.","Brenetafusp Phase 1/2 data in late-line cutaneous melanoma selected for oral presentation at ASCO 2024 (May 31).","KIMMTRAK launched in 7 additional countries since Jan 2024; now in 17 countries."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":70502000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1449726610.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227334,"accession_number":"0001140361-24-018342","cik":1671927,"company_name":"Immunocore Holdings plc","ticker":"IMCR","form_type":"8-K","filed_at":"2024-04-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immunocore files prospectus supplement for resale of 1,220,063 ADSs by selling shareholder","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Prospectus supplement filed on April 5, 2024, covering up to 1,220,063 ADSs for resale by a selling shareholder.","Each ADS represents one ordinary share of Immunocore with nominal value £0.002 per share.","Legal opinion from Cooley (UK) LLP regarding share validity included as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1449726610.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246214,"accession_number":"0001140361-24-010098","cik":1671927,"company_name":"Immunocore Holdings plc","ticker":"IMCR","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Immunocore FY2023 KIMMTRAK sales $238.7M; launches PRAME Phase 3 with BMS","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 KIMMTRAK net sales $67.6M; full year $238.7M (+12% YoY). US $169.8M, Europe $67.6M.","Net loss FY2023 $55.3M ($1.13 loss per share) vs $52.5M in 2022. R&D $163.5M, SG&A $144.5M.","Cash $442.6M at Dec 31; raised $389.3M net in Feb 2024 via 2.5% convertible notes due 2030.","Entered collaboration with BMS for Phase 3 PRISM-MEL301 trial of IMC-F106C + nivolumab in 1L advanced melanoma; first patient Q1 2024.","Multiple PRAME data readouts in 2024: cutaneous melanoma (Q2), ovarian (Q3), NSCLC (Q4). KIMMTRAK now in 12 launched countries."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":249428000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1449726610.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}